Tempus, a leader in artificial intelligence and precision medicine, has entered into a strategic research collaboration with Bristol Myers Squibb (BMY) to enhance cancer research and treatment. The partnership aims to identify and validate new targets in specific cancer disease areas, utilising multimodal datasets, computational approaches, and patient-derived disease models.
Ryan Fukushima, COO at Tempus, expressed excitement about expanding their collaboration with Bristol Myers Squibb, emphasising their joint commitment to advancing cancer research. By leveraging Tempus' multimodal data, biological modelling, and machine learning alongside Bristol Myers Squibb's discovery expertise, the teams aim to accelerate discoveries, innovate therapies, and improve outcomes for cancer patients.
The initial focus of the collaboration is on identifying new drug targets to broaden treatment options for patients lacking effective therapies or those refractory to existing treatments. The collaborative effort involves analysing disease cohorts within Tempus' extensive multimodal database and applying systems biology approaches.
Novel targets will be tested using Tempus' library of patient-derived organoids, resulting in a collaborative and iterative approach to research.
Click here to read the original news story.